Guardant Health has announced the launch of its Shield multi-cancer detection (MCD) blood test across selected Asia Pacific markets, expanding access to early cancer screening technologies.

• Test Capability: Methylation-based blood test designed to detect 10 cancer types, including lung, breast, colorectal, and liver cancers, in individuals aged 45 and above at average risk.
• Market Availability: To be introduced in Singapore, Hong Kong, and the Philippines from April 2026.
• Partnership: Collaboration with Manulife to support access to early cancer detection solutions in the region.

This summary is based on a news article by BioSpectrum Asia.

Image for illustrative purposes only. Source: Canva.